DARATUMUMAB
Corneal Disorder
Hellenic Society of Hematologymonoclonal_antibodyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Corneal Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Hellenic Society of Hematology | Phase 1/2 | CC |
cc-5013 Hellenic Society of Hematology | Phase 1/2 | CC |
gsk2857916 Hellenic Society of Hematology | Phase 1/2 | CC |
Pomalidomide Hellenic Society of Hematology | Phase 1/2 | CC |
Nirogacestat Hellenic Society of Hematology | Phase 1/2 | CC |
Cenegermin-Bkbj Tufts Medical Center | Phase 1 | CC |
HUMAN CORD BLOOD PLASMA Singapore Eye Research Institute | N/A | D |
Same molecule, other indications
DARATUMUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →